Prescient unveils new cancer-fighting technology in Boston
General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.
About this video
At the world’s largest CAR-TCR meeting in Boston, MA, Prescient Therapeutics (ASX: PTX) has debuted CellPryme-A, which is a novel adjuvant designed to be administered to cancer patients in combination with cellular immunotherapy such as CAR-T. Stephen Yatomi-Clark, Prescient's CEO and Managing Director, joins us to unpack this development.
Stephen says that CellPryme-A is an adjuvant that makes the tumour microenvironment more amenable to cellular immunotherapy and that it significantly improves tumour killing and survival. He says that the adjuvant strongly synergises with CellPryme-M, which Prescient unveiled in June this year.
The technology ca be incorporated into existing cell therapy programs and is ready for use in clinical trials.
Stephen welcomes external collaborations and applications in enhancing Prescient’s own OmniCAR programs.